Evaluation of candidate vaccine approaches for MERS-CoV

Nature Communications

Volumn 6, Issue , 2015, Pages

  Wang, Lingshu ^a   Shi, Wei ^a   Joyce, M Gordon ^a   Modjarrad, Kayvon ^a,b,c   Zhang, Yi ^a   Leung, Kwanyee ^a   Lees, Christopher R ^a   Zhou, Tongqing ^a   Yassine, Hadi M ^a   Kanekiyo, Masaru ^a   Yang, Zhi Yong ^a,d   Chen, Xuejun ^a   Becker, Michelle M ^e   Freeman, Megan ^e   Vogel, Leatrice ^a   Johnson, Joshua C ^f   Olinger, Gene ^f   Todd, John P ^a   Bagci, Ulas ^f,g   Solomon, Jeffrey ^f   Mollura, Daniel J ^f   Hensley, Lisa ^f   Jahrling, Peter ^f   Denison, Mark R ^e   Rao, Srinivas S ^a   Subbarao, Kanta ^a   Kwong, Peter D ^a   Mascola, John R ^a   Kong, Wing Pui ^a   Graham, Barney S ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d Sanofi Aventis   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g University of Central Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; VIRUS VACCINE; CORONAVIRUS SPIKE GLYCOPROTEIN; DNA VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY; BIOASSAY; DISEASE SEVERITY; IMMUNIZATION; NEUTRALIZATION; PRIMATE; PROTEIN; RADIOGRAPHY; RESPIRATORY DISEASE; RODENT; TOMOGRAPHY; VACCINE; VIRAL DISEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; NONHUMAN; PROTEIN SUBUNIT; RHESUS MONKEY; VIRUS NEUTRALIZATION; VIRUS PNEUMONIA; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CORONAVIRUS INFECTIONS; HEK293 CELL LINE; IMMUNOLOGY;

MIDDLE EAST;

CORONAVIRUS; MACACA MULATTA; MURINAE; MUS; PRIMATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; VACCINES, DNA; VIRAL VACCINES;

EID: 84938149041     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8712     Document Type: Article

References (54)

1. ECDC. Epidemiological Update: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (European Centre for Disease Prevention and Control, 2014).
2. WHO. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Summary and Literature Update-as of 11 June 2014 (World Health Organization, 2014).
3. Assiri, A. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect. Dis. 13, 752-761 (2013).
4. Breban, R., Riou, J. & Fontanet, A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382, 694-699 (2013).
5. Cauchemez, S. et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect. Dis. 14, 50-56 (2014).
6. Memish, Z. A. et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 20, 1012-1015 (2014).
7. Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11, 836-848 (2013).
8. Cavanagh, D. Coronavirus IBV: structural characterization of the spike protein. J. Gen. Virol. 64 Pt 12 2577-2583 (1983).
9. Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. USA 101, 9804-9809 (2004).
10. Coleman, C. M. et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32, 3169-3174 (2014).
11. Du, L. et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS ONE 8, e81587 (2013).
12. Ma, C. et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32, 2100-2108 (2014).
13. Mou, H. et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379-9383 (2013).
14. Du, L. et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in middle east respiratory syndrome coronavirus spike protein. J. Virol. 88, 7045-7053 (2014).
15. Ohnuma, K. et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J. Virol. 87, 13892-13899 (2013).
16. Ying, T. et al. Exceptionally potent neutralization of middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88, 7796-7805 (2014).
17. Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 6, 234ra259 (2014).
18. Briese, T. et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. mBio 5, e01146-14 (2014).
19. Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26, 6338-6343 (2008).
20. Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561-564 (2004).
21. Naldini, L., Blomer, U., Gage, F. H., Trono, D. & Verma, I. M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl Acad. Sci. USA 93, 11382-11388 (1996).
22. Yang, Z. Y. et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl Acad. Sci. USA 102, 797-801 (2005).
23. Stevens, T. L. et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334, 255-258 (1988).
24. Davis, H. L., Schirmbeck, R., Reimann, J. & Whalen, R. G. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum. Gene. Ther. 6, 1447-1456 (1995).
25. Shedlock, D. J. & Weiner, D. B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68, 793-806 (2000).
26. Cargnelutti, D. E. et al. Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant. New Microbiol. 36, 145-151 (2013).
27. Chaitra, M. G., Nayak, R. & Shaila, M. S. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant. Vaccine 25, 7168-7176 (2007).
28. Lu, G. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227-231 (2013).
29. Prabakaran, P. et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J. Biol. Chem. 281, 15829-15836 (2006).
30. Zhu, Z. et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl Acad. Sci. USA 104, 12123-12128 (2007).
31. Mansoor, A. et al. A generic approach to pathological lung segmentation. IEEE Trans. Med. Imaging 33, 2293-2310 (2014).
32. Zhao, J. et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl Acad. Sci. USA 111, 4970-4975 (2014).
33. de Wit, E. et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE 8, e69127 (2013).
34. Tang, X. C. et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl Acad. Sci. USA 111, E2018-E2026 (2014).
35. Caulfield, M. J. et al. Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J. Virol. 76, 10038-10043 (2002).
36. Kong, W. P. et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. J. Virol. 79, 13915-13923 (2005).
37. Ledgerwood, J. E. et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11, 916-924 (2011).
38. Ledgerwood, J. E. et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J. Infect. Dis. 208, 418-422 (2013).
39. Khurana, S. et al. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J. Infect. Dis. 208, 413-417 (2013).
40. Sui, J. et al. Effects of human anti-spike protein receptor binding domain antibodies on SARS-coronavirus neutralization escape and fitness. J. Virol. 88, 13769-13780 (2014).
41. McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013).
42. McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
43. Barouch, D. H. et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79, 8828-8834 (2005).
44. Catanzaro, A. T. et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25, 4085-4092 (2007).
45. Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493-497 (1938).
46. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
47. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
48. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
49. Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr. D Biol. Crystallogr. 60, 2210-2221 (2004).
50. Fan, Z. C. et al. Three-dimensional structure of an Fv from a human IgM immunoglobulin. J. Mol. Biol. 228, 188-207 (1992).
51. Pak, J. E. et al. Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain. J. Mol. Biol. 388, 815-823 (2009).
52. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta. Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
53. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta. Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
54. Scobey, T. et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 110, 16157-16162 (2013).